|
 |
HIV Patients & Cancer |
A new research suggests that the weakened immune systems of people with HIV puts them at increased risk for at least seven types of cancer, but early diagnosis and treatment of HIV infection could help delay the onset of some of these cancers.
Researchers examined the incidence of three aids-defining cancers (Kaposi’s sarcoma, non-Hodgkin’s lymphoma and cervical cancer) and four non-aids-defining cancers (Hodgkin’s lymphoma, lung cancer, liver cancer and anal cancer) in 52,278 HIV-infected people.
The study authors also analyzed the association between immunodeficiency, viral load, antiretroviral treatment and the onset of the seven cancers. Overall, immunodeficiency increased the risk of all the cancers, and CD4 cell count was the most predictive risk factor for all the cancers except anal cancer. The cancer risk associated with viral load was lower than that associated with immunodeficiency, the researchers noted.
Now, I will introduce 4-Nitrophenyl Chloroformate (CAS代碼：7693-46-1) to you. This is used as a pharmaceutical Intermediates of anti-HIV. If you are interested in this pharmaceutical Intermediates, you can have more information at www.elbenab.com.
|
Published:2009-10-13 |
|
|
|
|
|
.png){kind=small}